IgA Nephropathy News and Research

RSS

IgA nephropathy (IgAN), also known as Berger’s disease, is the leading cause of primary glomerulonephritis all over the world. It is autoimmune in origin, characterized by the stimulation of genetically determined formation of concentration of IgA1 with galactose-deficient O-glycans in the hinge-region (Hit 1) in the blood. These stimulate anti-glycan antibody production, followed by binding with the aberrantly glycated IgA1.

Kidney Week 2026 features late-breaking clinical trials in kidney care

The American Society of Nephrology, has selected the following late breaking clinical trials to be presented in-person at Kidney Week 2026 October 22–25.

24 Oct 2026

CFHR1 could be a new diagnostic marker for IgA nephropathy

Immunoglobulin A (IgA) nephropathy is an autoimmune disease characterized by the deposition of circulating IgA-containing immune complexes (IgA-ICs) in the glomerular mesangium, leading to mesangial cell proliferation, enhanced extracellular matrix production, and variable infiltration of inflammatory cells.

30 Mar 2026

Social living allows genetic effects to spread through the gut microbiome

Your "roommate's" genes could be influencing the bacteria living in your gut, and vice versa, according to a study of rats published today in Nature Communications.

18 Dec 2025

Pediatric patients with primary glomerular diseases may experience faster kidney function decline

New research reveals that contrary toconventional belief, primary glomerular diseases are not necessarily benign for children and young adults. In fact, some subsets of children and young adults may experience faster kidney function decline than older patients.

7 Nov 2025

Aptamer signs therapeutic development agreement with Invizius

Aptamer Group plc, the developer of next-generation synthetic binders for the life sciences industry, is pleased to announce that it has signed a new therapeutic development agreement with Invizius, a clinical-stage biotechnology company focused on second-generation complement system therapies for inflammatory, fibrotic, and autoimmune diseases.

From Aptamer Group 2 Sep 2025

New data shows zigakibart sustains proteinuria remission and kidney function in IgA nephropathy

New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, reinforce its potential as a disease-modifying treatment for IgA nephropathy (IgAN).

5 Jun 2025

Study identifies novel IgAN loci through pleiotropy

IgA nephropathy (IgAN) is a prevalent form of primary glomerulonephritis characterized by the deposition of IgA in the glomerular mesangium, leading to a spectrum of histopathological lesions and a variable clinical course that can progress to end-stage renal disease in a significant proportion of patients.

2 Jan 2025

Novel gene therapy PS-002 targets podocytes in IgA nephropathy

IgA nephropathy is an autoimmune kidney disease, and complement, a component of the innate immune system, plays a role in the condition's pathogenesis.

27 Oct 2024

New trial shows felzartamab reduces proteinuria in IgA nephropathy patients

IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface.

26 Oct 2024

Understanding gluten's role in autoimmunity and inflammation

The interaction between humans and their environment, mediated by nutrition, plays a crucial role in regulating inflammatory responses.

21 Aug 2024

6th CKD Drug Development Summit: Countdown Begins

...

From 6th CKD Drug Development Summit 16 Feb 2024

High-impact clinical trial results to be presented at ASN Kidney Week 2023

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2023 November 1–November 5.

3 Nov 2023

Do prebiotics and probiotics positively impact cardiovascular and renal health?

The benefits of consuming nutrients, prebiotics, and probiotics to enhance cardiovascular and renal health.

11 Oct 2023

Study supports vaccination for COVID-19 in patients with glomerular diseases

Among 2,055 adults with a wide range of glomerular diseases, the COVID-19 vaccination did not adversely affect kidney function or worsen kidney damage and appeared safe in this population.

5 Sep 2023

IgA nephropathy: The disease that lies outside the kidney

The cause of a common kidney disease likely lies outside the kidney, according to a new study led by Columbia University researchers.

23 Jun 2023

$New facile strategy for proteome analysis using ultracentrifugation fractionation$

New facile strategy for proteome analysis using ultracentrifugation fractionation

Urine is one of the attractive sources for early and sensitive biomarker discovery since it can accumulate and reflect changes in the human body while being collected non-invasively.

16 Jun 2023

Study finds low absolute risk of glomerular disease relapse associated with COVID-19 vaccination

Several reports have described a relapse of certain autoimmune kidney diseases in patients after they've received COVID-19 vaccines, but it's unclear if this association is real or a coincidence.

4 Nov 2022

Adults with primary glomerular disease have high cardiovascular risk, study shows

Among almost 2,000 adults with primary glomerular disease followed for a median of 6.8 years, risk of cardiovascular events including coronary artery, cerebrovascular, and peripheral vascular events, and death due to myocardial infarction or stroke was 2.5-fold higher compared to the general population.

1 Jun 2022

Study shows glomerulonephritis after SARS-CoV-2 mRNA vaccination likely coincidental

In a recent study posted to the medRxiv* pre-print server, researchers assessed whether messenger ribonucleic acid (mRNA)-based coronavirus disease 2019 (COVID-19) vaccines increase the incidence of glomerulonephritis against the null hypothesis stating any observed temporal association between the two phenomena was purely coincidental.

26 May 2022

Multi-country study provides a clear treatment option for IgA nephropathy

The largest ever randomized controlled trial in IgA nephropathy has found that treatment with methylprednisolone - a cheap, widely used corticosteroid drug - halves the risk of losing kidney function and kidney failure, and that this can be effectively achieved with fewer side effects if a reduced dose is used.

17 May 2022